Quantify how many countries supply your API. Origin country count, share of leading origin, and the share of supply concentrated outside the dominant origin.
Of 8,084 (molecule, importer) pairs visible in the 2024 trade record, 8,047 (99.5%) are served from a single origin country. Only 37 pairs (0.5%) draw from two or more origins. The trade graph is structurally single-origin at the working unit; diversification is the exception, not the baseline.
Type the INN. The AI agent pulls every export-origin country with observable shipments on the molecule, last two years.
Distinct origin countries, share of the leading origin, share outside the top origin. Normalised to a 0-to-1 single-origin score.
Citation-anchored brief with the origin breakdown, dominant-origin share trajectory, and a chip showing diversification grade.
A molecule sourced from one country is a different risk than a molecule sourced from three. Origin-level concentration sits above lane-level HHI and is often invisible until disruption hits.
An origin moving from 95% to 99% share is a deteriorating signal even before any one supplier disrupts. The brief tracks share quarter on quarter.
Single-origin, dominant-origin, balanced, or distributed. The grade chip is the one-look signal on the catalog row.
Trade aggregates refresh weekly. Origin share movement propagates on the next refresh.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Twenty molecules · dominant-origin share, latest two years · HHI proxy on the 0 to 1 single-origin scale.
Origin diversification is the above-the-lane view of supply concentration. PharmaDB joins trade aggregates to the molecule catalog and reports distinct origin countries plus dominant-origin share so single-origin exposure surfaces before disruption hits. The view rests on molecule_country_flow. Refresh cadence is weekly.
Lane HHI measures concentration of exporters within a single origin-destination lane. Origin diversification measures concentration of countries supplying the molecule globally. A lane can look competitive at HHI 0.3 while the molecule remains single-origin (one country, many exporters).
The observable customs trace for tirzepatide API in 2024 and 2025 is 100% Indian-export. Other origins may have unreported flows or be supplying domestic markets that the trade feed does not capture. PharmaDB labels these gaps explicitly when the data confidence is partial.
Yes, the spread within Indian dominance varies considerably. Some molecules show 60 percent India with meaningful supply from China, Italy, or Spain. Others show 99 percent India. The grade chip surfaces this gradation; lane HHI does not.
A single-origin molecule needs a different dual-source strategy than a multi-origin one. The latter can dual-source within current supply geography; the former requires qualifying a supplier in a new country, which is a longer regulatory project.
The headline metric is API-level. The companion analysis, China intermediate dependency map, surfaces upstream KSM exposure where Indian APIs depend on Chinese intermediates not visible in the API trade feed.
Weekly. Trade aggregates refresh weekly; origin share is recomputed on every refresh. The catalog row carries an as-of timestamp on every result page.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.